| Dr Steven R Prince, MD | |
|
2240 Sutherland Ave, Suite 104, Knoxville, TN 37919-2333 | |
| (865) 909-0090 | |
| (865) 909-9883 |
| Full Name | Dr Steven R Prince |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 43 Years |
| Location | 2240 Sutherland Ave, Knoxville, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598724791 | NPI | - | NPPES |
| 38798011 | Medicaid | TN | |
| 3717541 | Other | TN | MEDICARE GROUP # |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 26765 (Tennessee) | Primary |
| 207R00000X | Internal Medicine | 0101034772 (Virginia) | Secondary |
| 207R00000X | Internal Medicine | 26765 (Tennessee) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Greeneville Community Hospital | Greeneville, TN | Hospital |
| Johnson City Medical Center | Johnson city, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Blue Ridge Medical Management Corporation | 9739099441 | 308 |
News Archive
Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that it has filed for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for INFRADURE for the treatment of hepatitis D.
VIVUS, Inc. today announced that data on Qnexa(TM), an investigational new drug, will be presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley Day, PhD, vice president of clinical development at VIVUS, will present data from the company's two year long phase 3 obesity trials, and Dr. Timothy Garvey, MD, professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham, will present data from the year long phase 2 study in type 2 diabetics.
Quintiles today announced a strategic alliance with leading global pharmaceutical company Eisai Co., Ltd. (Tokyo, Japan) to develop six potential oncology products in Eisai's R&D pipeline. Under the terms of the agreement, Quintiles' oncology experts will conduct Phase II proof-of-concept studies for 11 solid tumor indications. A key goal of the alliance is to determine the efficacy of the products in the shortest possible time in order to bring therapies to market faster for the benefit of cancer patients worldwide.
The continuing efforts to make progress on the nation's health overhaul are reflected in today's headlines, which highlight both politics and policies.
Violence, sex, and profanity increased significantly in movies between 1992 and 2003 according to a study by researchers from the Kids Risk Project at the Harvard School of Public Health. The study appears July 13 in Medscape General Medicine.
› Verified 4 days ago
| Entity Name | Summit Medical Group, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659090298 PECOS PAC ID: 2860396330 Enrollment ID: O20031125000793 |
News Archive
Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that it has filed for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for INFRADURE for the treatment of hepatitis D.
VIVUS, Inc. today announced that data on Qnexa(TM), an investigational new drug, will be presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley Day, PhD, vice president of clinical development at VIVUS, will present data from the company's two year long phase 3 obesity trials, and Dr. Timothy Garvey, MD, professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham, will present data from the year long phase 2 study in type 2 diabetics.
Quintiles today announced a strategic alliance with leading global pharmaceutical company Eisai Co., Ltd. (Tokyo, Japan) to develop six potential oncology products in Eisai's R&D pipeline. Under the terms of the agreement, Quintiles' oncology experts will conduct Phase II proof-of-concept studies for 11 solid tumor indications. A key goal of the alliance is to determine the efficacy of the products in the shortest possible time in order to bring therapies to market faster for the benefit of cancer patients worldwide.
The continuing efforts to make progress on the nation's health overhaul are reflected in today's headlines, which highlight both politics and policies.
Violence, sex, and profanity increased significantly in movies between 1992 and 2003 according to a study by researchers from the Kids Risk Project at the Harvard School of Public Health. The study appears July 13 in Medscape General Medicine.
› Verified 4 days ago
| Entity Name | Blue Ridge Medical Management Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144380833 PECOS PAC ID: 9739099441 Enrollment ID: O20031204000996 |
News Archive
Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that it has filed for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for INFRADURE for the treatment of hepatitis D.
VIVUS, Inc. today announced that data on Qnexa(TM), an investigational new drug, will be presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley Day, PhD, vice president of clinical development at VIVUS, will present data from the company's two year long phase 3 obesity trials, and Dr. Timothy Garvey, MD, professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham, will present data from the year long phase 2 study in type 2 diabetics.
Quintiles today announced a strategic alliance with leading global pharmaceutical company Eisai Co., Ltd. (Tokyo, Japan) to develop six potential oncology products in Eisai's R&D pipeline. Under the terms of the agreement, Quintiles' oncology experts will conduct Phase II proof-of-concept studies for 11 solid tumor indications. A key goal of the alliance is to determine the efficacy of the products in the shortest possible time in order to bring therapies to market faster for the benefit of cancer patients worldwide.
The continuing efforts to make progress on the nation's health overhaul are reflected in today's headlines, which highlight both politics and policies.
Violence, sex, and profanity increased significantly in movies between 1992 and 2003 according to a study by researchers from the Kids Risk Project at the Harvard School of Public Health. The study appears July 13 in Medscape General Medicine.
› Verified 4 days ago
| Entity Name | App Of Tennessee Hm, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396160768 PECOS PAC ID: 5395960694 Enrollment ID: O20140630001088 |
News Archive
Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that it has filed for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for INFRADURE for the treatment of hepatitis D.
VIVUS, Inc. today announced that data on Qnexa(TM), an investigational new drug, will be presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley Day, PhD, vice president of clinical development at VIVUS, will present data from the company's two year long phase 3 obesity trials, and Dr. Timothy Garvey, MD, professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham, will present data from the year long phase 2 study in type 2 diabetics.
Quintiles today announced a strategic alliance with leading global pharmaceutical company Eisai Co., Ltd. (Tokyo, Japan) to develop six potential oncology products in Eisai's R&D pipeline. Under the terms of the agreement, Quintiles' oncology experts will conduct Phase II proof-of-concept studies for 11 solid tumor indications. A key goal of the alliance is to determine the efficacy of the products in the shortest possible time in order to bring therapies to market faster for the benefit of cancer patients worldwide.
The continuing efforts to make progress on the nation's health overhaul are reflected in today's headlines, which highlight both politics and policies.
Violence, sex, and profanity increased significantly in movies between 1992 and 2003 according to a study by researchers from the Kids Risk Project at the Harvard School of Public Health. The study appears July 13 in Medscape General Medicine.
› Verified 4 days ago
| Entity Name | Statcare Inpatient Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477086981 PECOS PAC ID: 5496025074 Enrollment ID: O20170714002608 |
News Archive
Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that it has filed for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for INFRADURE for the treatment of hepatitis D.
VIVUS, Inc. today announced that data on Qnexa(TM), an investigational new drug, will be presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley Day, PhD, vice president of clinical development at VIVUS, will present data from the company's two year long phase 3 obesity trials, and Dr. Timothy Garvey, MD, professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham, will present data from the year long phase 2 study in type 2 diabetics.
Quintiles today announced a strategic alliance with leading global pharmaceutical company Eisai Co., Ltd. (Tokyo, Japan) to develop six potential oncology products in Eisai's R&D pipeline. Under the terms of the agreement, Quintiles' oncology experts will conduct Phase II proof-of-concept studies for 11 solid tumor indications. A key goal of the alliance is to determine the efficacy of the products in the shortest possible time in order to bring therapies to market faster for the benefit of cancer patients worldwide.
The continuing efforts to make progress on the nation's health overhaul are reflected in today's headlines, which highlight both politics and policies.
Violence, sex, and profanity increased significantly in movies between 1992 and 2003 according to a study by researchers from the Kids Risk Project at the Harvard School of Public Health. The study appears July 13 in Medscape General Medicine.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Steven R Prince, MD 1225 E Weisgarber Rd, Suite 200, Knoxville, TN 37909-2604 Ph: (865) 584-4747 | Dr Steven R Prince, MD 2240 Sutherland Ave, Suite 104, Knoxville, TN 37919-2333 Ph: (865) 909-0090 |
News Archive
Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that it has filed for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for INFRADURE for the treatment of hepatitis D.
VIVUS, Inc. today announced that data on Qnexa(TM), an investigational new drug, will be presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley Day, PhD, vice president of clinical development at VIVUS, will present data from the company's two year long phase 3 obesity trials, and Dr. Timothy Garvey, MD, professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham, will present data from the year long phase 2 study in type 2 diabetics.
Quintiles today announced a strategic alliance with leading global pharmaceutical company Eisai Co., Ltd. (Tokyo, Japan) to develop six potential oncology products in Eisai's R&D pipeline. Under the terms of the agreement, Quintiles' oncology experts will conduct Phase II proof-of-concept studies for 11 solid tumor indications. A key goal of the alliance is to determine the efficacy of the products in the shortest possible time in order to bring therapies to market faster for the benefit of cancer patients worldwide.
The continuing efforts to make progress on the nation's health overhaul are reflected in today's headlines, which highlight both politics and policies.
Violence, sex, and profanity increased significantly in movies between 1992 and 2003 according to a study by researchers from the Kids Risk Project at the Harvard School of Public Health. The study appears July 13 in Medscape General Medicine.
› Verified 4 days ago
Daniel Eugene Brewer, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1924 Alcoa Hwy, U56, Knoxville, TN 37920 Phone: 865-305-9081 Fax: 865-305-8769 | |
Dr. Ryan Douglas Kerr, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1924 Alcoa Hwy, U56, Knoxville, TN 37920 Phone: 865-305-9081 Fax: 865-305-8769 | |
Landy M Morales, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1924 Alcoa Hwy, Box 56, Knoxville, TN 37920 Phone: 865-305-9081 Fax: 865-305-8769 | |
Sahar M Lotfi, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1924 Alcoa Hwy, U56, Knoxville, TN 37920 Phone: 865-305-9081 Fax: 865-305-8769 | |
Dr. Clayton Devereau Humphrey, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1924 Alcoa Hwy # U56, Knoxville, TN 37920 Phone: 865-305-9081 Fax: 865-305-8769 | |
Dr. Christopher Hill, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1924 Alcoa Hwy # U56, Knoxville, TN 37920 Phone: 865-305-9081 Fax: 865-305-8769 | |
Murad Salaita, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1924 Alcoa Hwy, U56, Knoxville, TN 37920 Phone: 865-305-9081 Fax: 865-305-8769 |